Table 2.
Comparison Between Specimen Type and Testing Results for Cases
| Groups by Available Specimens | No. | Count of Positive Patients by Study PCR | Percentage Positive by Study PCR | Count of Positive by Any Testing Method in Row | Percentage Positive by Any Testing Method in Row | Percent Increase in RSV Detection |
|---|---|---|---|---|---|---|
| 3 specimens | ||||||
| Study PCR, SOC, serology any | 323 | 24 | 7.4 | 37 | 11.5 | 55.4 |
| Study PCR, SOC, serology 1 | 323 | 24 | 7.4 | 33 | 10.2 | 37.8 |
| Study PCR, SOC, serology 2 | 164 | 12 | 7.3 | 18 | 11.0 | 50.7 |
| Study PCR, SOC, sputum | 78 | 3 | 3.9 | 4 | 5.2 | 33.3 |
| Study PCR, serology any, sputum | 57 | 0 | 0.0 | 1 | 1.7 | NA |
| Study PCR, serology 1, sputum | 57 | 0 | 0.0 | 1 | 1.7 | NA |
| Study PCR, serology 2, sputum | 8 | 0 | 0.0 | 0 | 0.0 | NA |
| 2 specimens | ||||||
| Study PCR, SOC | 805 | 47 | 5.8 | 59 | 7.3 | 25.9 |
| Study PCR, serology any | 568 | 28 | 4.9 | 40 | 7.0 | 42.9 |
| Study PCR, serology collected ≤5 d from symptom onset | 361 | 13 | 3.6 | 19 | 5.3 | 46.2 |
| Study PCR, serology collected >5 d from symptom onset | 207 | 15 | 7.3 | 21 | 10.1 | 38.4 |
| Study PCR, serology 1 | 568 | 28 | 4.9 | 31 | 5.5 | 12.2 |
| Study PCR, serology 2 | 268 | 15 | 5.6 | 24 | 9.0 | 60.7 |
| Study PCR, sputum | 153 | 4 | 2.6 | 5 | 3.3 | 26.9 |
| 1 specimen | ||||||
| Study PCR | 1558 | … | … | 69 | 4.4 | … |
| NP/OP | 1558 | … | … | 58 | 3.7 | … |
| NP, previous NP/OP negative only | 742 | … | … | 10 | 1.3 | … |
| OP, previous NP/OP negative only | 740 | … | … | 3 | 0.4 | … |
| SOC NP PCR | 805 | … | … | 58 | 7.2 | … |
| Serology | 568 | … | … | 28 | 4.9 | … |
| Acute specimen collected ≤5 d from symptom onset | 361 | … | … | 14 | 3.9 | … |
| Acute specimen collected >5 d from symptom onset | 207 | … | … | 14 | 6.8 | … |
| Serology 1 | 568 | … | … | 19 | 3.4 | … |
| Serology 2 | 268 | … | … | 16 | 6.0 | … |
| Sputum | 153 | … | … | 5 | 3.3 | … |
Study PCR represents all who had a research specimen (combined NP/OP or stand-alone NP or OP) tested by BioFire respiratory panel. Initially, NP and OP VTM was combined and tested; those that were negative by this approach had NP and OP VTM tested separately. SOC represents all who had standard-of-care nucleic acid amplification testing of an NP specimen for RSV. Serology 1 represents IgG binding to RSV lysate as measured by ELISA. Serology 2 represents IgG binding to either RSV F, G, M, or N by multiplexed serology platform. Sputum represents all who had an expectorated sputum sample available for BioFire respiratory panel analysis. Percent increase in RSV detection represents the percentage increase in detection of RSV using the methods in the row above the BioFire results alone.
Abbreviations: ELISA, enzyme-linked immunosorbent assay; NA, not applicable; NP, nasopharyngeal; OP, oropharyngeal; PCR, polymerase chain reaction; RSV, respiratory syncytial virus; SOC, standard-of-care; VTM, viral transport medium.